Aralez Pharmaceuticals announced the United States District Court for the District of New Jersey upheld the validity of two patents owned by a subsidiary of Aralez.
Aralez Pharmaceuticals (NASDAQ:ARLZ; TSX:ARZ) announced the United States District Court for the District of New Jersey upheld the validity of two patents owned by a subsidiary of the company and licensed to several pharmaceutical companies and medical officers.
As quoted in the press release:
On April 21, 2011, July 25, 2011, and June 28, 2013, an Aralez subsidiary filed patent infringement lawsuits in District Court against Dr. Reddy’s, Lupin, and Mylan, respectively, related to Abbreviated New Drug Applications filed with the U.S. Food and Drug Administration to market generic versions of VIMOVO. The lawsuits claim infringement of U.S. Patent Nos. 8,557,285 (‘285 patent) and 6,926,907 (‘907 patent) titled “Pharmaceutical Compositions for the Coordinated Delivery of NSAIDs,” which cover VIMOVO. The District Court’s decision was made based on the validity of the ‘285 and ‘907 patents for VIMOVO and the Court’s judgment will prevent Dr. Reddy’s, Mylan, and Lupin from launching generic versions of VIMOVO in the United States until at least the expiration of the relevant patent.
“We are very pleased that the fair and appropriate ruling regarding this litigation was rendered by the United States District Court for the District of New Jersey,” said Adrian Adams, Chief Executive Officer of Aralez. “This demonstrates the strength of our intellectual property portfolio for VIMOVO and Yosprala®. We remain committed to aggressively defending our intellectual property.”